Research Topics
Genomes and Genes | Hans R BrunnerSummaryAffiliation: Centre Hospitalier Universitaire Vaudois Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
The new oral angiotensin II antagonist olmesartan medoxomil: a concise overviewHans R Brunner
Division of Hypertension and Vascular Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
J Hum Hypertens 16:S13-6. 2002..Clinical pharmaco- dynamic and efficacy studies support a usual dose of 20 mg once daily, increasing to 40 mg if needed...- Clinical efficacy of olmesartan medoxomilHans R Brunner
Division of Hypertension and Vascular Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
J Hypertens Suppl 21:S43-6. 2003..In head-to-head studies, olmesartan delivered superior blood pressure reduction when compared with other angiotensin-II receptor antagonists at their recommended doses... - Angiotensin blockade for hypertension: a promise fulfilledHans R Brunner
Division of Hypertension and Vascular Medicine, CHUV, 1011, Lausanne, Switzerland
Lancet 359:990-2. 2002 - In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonistMarc P Maillard
Division of Hypertension and Vascular Medicine, University Hospital of Lausanne, CHUV CH 1011 Lausanne, Switzerland
J Pharmacol Exp Ther 302:1089-95. 2002..Taken together, our in vitro data show that the insurmountable antagonism of telmisartan is due at least in part to its very slow dissociation from AT1 receptors... - Renal endothelin receptor type B upregulation in rats with low or high renin hypertensionNoureddine Brakch
Division of Hypertension and Vascular Medicine, University Hospital, CH 1011 Lausanne, Switzerland
J Hypertens 22:1797-803. 2004..To evaluate the role of endothelin-1 (ET-1) in hypertension, we investigated density and distribution of ETA and ETB receptors in hearts and kidneys of deoxycorticosterone acetate (DOCA)-salt and 1 kidney -- 1 clip (1K1C) hypertensive rats... - Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosingMarc P Maillard
Division of Hypertension and Vascular Medicine, University Hospital of Lausanne, Switzerland
Clin Pharmacol Ther 71:68-76. 2002..In this study we investigated the importance of drug dosing in mediating these differences by comparing the AT(1)-receptor blockade induced by 3 doses of valsartan with that obtained with 3 other antagonists at given doses... - Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- miceLucia Mazzolai
Service of Angiology, CHUV, University of Lausanne, 1011 Lausanne, Rue du Bugnon 46, Switzerland
Hypertension 44:277-82. 2004.... - Determination of cardiac contractility in awake unsedated mice with a fluid-filled catheterQing Wang
Division of Hypertension and Vascular Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Am J Physiol Heart Circ Physiol 286:H806-14. 2004..These data demonstrate that cardiac contractility can be measured very accurately in conscious mice. This new device can be of great help in the investigation of cardiac function in normal and genetically engineered mice... - Clinical efficacy and tolerability of olmesartanHans R Brunner
Division of Hypertension and Vascular Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Clin Ther 26:A28-32. 2004..Olmesartan, with or without hydrochlorothiazide, was well tolerated over 2 years of treatment... - Blood sampling methodology is crucial for precise measurement of plasma catecholamines concentrations in miceEric Grouzmann
Division of Clinical Pharmacology and Toxicology, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
Pflugers Arch 447:254-8. 2003..In conclusion, arterial-catheter and retro-orbital blood sampling methods appear to be the most accurate procedures for studying the sympathetic nervous system in mice in both unstressed and stressed conditions... - Neuropeptide Y expression, localization and cellular transducing effects in HUVECAntonio P Silva
Division d Hypertension et de Médecine Vasculaire, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Biol Cell 97:457-67. 2005..The aim of the present study was to establish NPY expression, storage and cellular transducing effects in HUVEC... - Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genesQing Wang
Division of Hypertension and Vascular Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
J Am Soc Nephrol 13:1509-16. 2002..Finally, these data provide further evidence that mineralocorticoids promote cardiac hypertrophy even in the absence of BP changes. This hypertrophic process is mediated in part by the activation of angiotensin II AT(1) receptors... - NPY, NPY receptors, and DPP IV activity are modulated by LPS, TNF-alpha and IFN-gamma in HUVECAntonio P Silva
, Centre Hospitalier Universitaire Vaudois, 1011, Lausanne, Switzerland
Regul Pept 116:71-9. 2003..The modulation of the NPY system by LPS, TNF-alpha and IFN-gamma, and the NPY-induced calcium signaling suggest a role for NPY during the inflammatory response... - Dibasic cleavage site is required for sorting to the regulated secretory pathway for both pro- and neuropeptide YNoureddine Brakch
Division of Hypertension and Vascular Medicine, University Hospital, Lausanne, Switzerland
J Neurochem 81:1166-75. 2002..ProNPY secretion behaviour was not Proteolytic cleavage efficiency-dependent. The dibasic cleavage was essential for ProNPY and NPY cAMP-dependent regulated secretion and may have function as a retention signal... - The neuropeptide Y Y1 receptor regulates leptin-mediated control of energy homeostasis and reproductive functionsFrancois P Pralong
Division of Endocrinology, Diabetology and Metabolism, University of Lausanne Medical School, CH 1011 Lausanne, Switzerland
FASEB J 16:712-4. 2002..Results point to a crucial role for the NPY Y1 receptor in mediating the NPY pathways situated downstream of leptin actions and controlling food intake, the onset of puberty, and the maintenance of reproductive functions... - Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteersChantal Csajka
Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland
Clin Pharmacokinet 41:137-52. 2002..To compare the pharmacokinetic and pharmacodynamic characteristics of angiotensin II receptor antagonists as a therapeutic class... - Monitoring compliance in resistant hypertension: an important step in patient managementMichel Burnier
Policlinique Medicale Universitaire, Division of Hypertension and Vascular Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
J Hypertens Suppl 21:S37-42. 2003.... - Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalaprilJuerg Nussberger
Division of Hypertension and Vascular Medicine, University Hospital Lausanne, Switzerland
Hypertension 39:E1-8. 2002..Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases... - Angiotensin II mediates catecholamine and neuropeptide Y secretion in human adrenal chromaffin cells through the AT1 receptorClaudia Cavadas
Division of Hypertension and Vascular Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
Regul Pept 111:61-5. 2003..These findings demonstrate that AT(1) stimulation induces catecholamine secretion from human adrenal chromaffin cells probably by raising cytosolic calcium... - Evolution and hypertension: is the Renin system necessary?Haralambos Gavras
Hypertension 49:e36; author reply e37. 2007 - Olmesartan medoxomil: current status of its use in monotherapyHans R Brunner
Lausanne University, Lausanne and Medizinische Poliklik, Universitaetsspital, Basel, Switzerland
Vasc Health Risk Manag 2:327-40. 2006..The efficacy of olmesartan medoxomil in reducing cardiovascular risk beyond BP reduction is currently being investigated in trials involving patients at high risk due to atherosclerosis or type 2 diabetes... - Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goalsHans R Brunner
Lausanne University, Medizinische Poliklinik, Universitaetsspital, Basel, Switzerland
Clin Drug Investig 26:185-93. 2006.... - The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapyStevo Julius
University of Michigan, Department of Internal Medicine, Division of Cardiovascular Medicine, 24 Frank Lloyd Wright Dr, PO Box 322, Lobby M, Ann Arbor, MI 48106, USA
Hypertension 48:385-91. 2006..Moreover, these findings support the feasibility of comparative prospective trials in lower-risk hypertensive patients... - Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitorChristopher Hasler
, Centre Hospitalier Universitaire Vaudois
Clin Pharmacol Ther 78:501-7. 2005..Hence, a higher dose of a long-acting ARB is as effective as a lower dose of the same compound combined with an angiotensin-converting enzyme inhibitor in terms of blockade of the vascular effects of angiotensin... - Magnesium supplementation and deoxycorticosterone acetate--salt hypertension: effect on arterial mechanical properties and on activity of endothelin-1Nathalie Berthon
Laboratoire Physiologie, Pharmacologie et Nutrition Préventive Expérimentale, UFR Médecine et Pharmacie, Universite de Franche Comte, Besancon, France
Can J Physiol Pharmacol 80:553-61. 2002..These findings suggest that Mg supplementation prevents blood pressure elevation by attenuating peripheral resistance and by decreasing hypertrophic effect of endothelin-1 via inhibition of endothelin-1 production... - Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialMichael A Weber
State University of New York, Brooklyn, NY, USA
Lancet 363:2049-51. 2004.... - Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialStevo Julius
University of Michigan, Ann Arbor, USA
Lancet 363:2022-31. 2004.... - Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?Andrei Forclaz
Division of Hypertensive and Vascular Medicine, University Hospital of Lausanne, Switzerland
Hypertension 41:31-6. 2003..A 24-hour blockade can be achieved with an angiotensin antagonist alone, provided higher doses or a BID regimen is used... - Renal hemodynamic and tubular responses to salt in women using oral contraceptivesAntoinette Pechere-Bertschi
Policlinique of Medicine and Division of Endocrinology, Reproduction and Chemical Laboratories University Hospital, Geneva, Switzerland
Kidney Int 64:1374-80. 2003..The purpose of the present study was to assess prospectively the systemic and renal hemodynamic and tubular responses to salt in women taking oral contraceptives... - Under pressure: future prospects in hypertension management. Interview by Laura DormerHans R Brunner
Expert Rev Cardiovasc Ther 6:921-3. 2008..Professor Brunner has been a medical advisor to Speedel since 1999... - Catecholamine and neuropeptide Y secretion from human adrenal chromaffin cells: effect of nicotine and KClClaudia Cavadas
Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal
Ann N Y Acad Sci 971:332-4. 2002 - Validation of in-vitro data by in-vivo evidence: the example of angiotensin (1-7)Hans R Brunner
J Hypertens 24:1919-20. 2006